title: Preservation of cognitive function in primary CNS lymphoma survivors a median of 12 years after enhanced chemotherapy delivery.
authors.affiliation: Oregon Health and Science University, Portland, OR.
authors.forename: Nancy D
authors.initials: ND
authors.lastname: Doolittle
authors.forename: Edit
authors.initials: E
authors.lastname: Dósa
authors.forename: Rongwei
authors.initials: R
authors.lastname: Fu
authors.forename: Leslie L
authors.initials: LL
authors.lastname: Muldoon
authors.forename: Leeza M
authors.initials: LM
authors.lastname: Maron
authors.forename: Meredith A
authors.initials: MA
authors.lastname: Lubow
authors.forename: Rose Marie
authors.initials: RM
authors.lastname: Tyson
authors.forename: Cynthia A
authors.initials: CA
authors.lastname: Lacy
authors.forename: Dale F
authors.initials: DF
authors.lastname: Kraemer
authors.forename: Robert W
authors.initials: RW
authors.lastname: Butler
authors.forename: Edward A
authors.initials: EA
authors.lastname: Neuwelt
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D003072:Cognition Disorders / Q000139:chemically induced / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D017741:Survivors / Q000706:statistics & numerical data
chemical_list: D000970:Antineoplastic Agents